# Big Data: Where are we now - and in 10 years?

Matthew Burriesci PhD

# We can achieve some great things in 10 years

- Wearables and desktop testing stations will better detect and manage diseases
- Genetics and blood chemistry of patients will be used to customize individual treatments
- Analytics will suggest which facilities provide the best care for specific conditions








#### We need to build a strong foundation now

- We can enable sharing of certain information while protecting privacy
- Install technology (computers and other infrastructure) to enable the next 10 years of advances



### Actions now: privacy-sensitive sharing

- Need to assure privacy is well respected
  - Anonymized data provides benefits
  - Some patients "opt into" sharing to help others this should be responsibly supported
- For best patient service, it is necessary to at least share a patient's records between hospitals
  - Electronic sharing can be more secure than physical sharing
  - Quicker sharing can lead to better care

#### Actions now: Modernize technology

- Get paper and film records digitised
- Convince all doctors to use electronic methods to enter data
  - iPads can help
  - Some doctors may need transcriptionists
- Decide how long to store data<sup>1</sup>
- Match outcomes with patient records to enable analytics





1 <u>Storage costs of electronic health records surprisingly low</u> Prepare for disasters tackle terabytes when evaluating medical image archiving

#### Wearables

- Remind people to stay healthy through "gamification" of health<sup>1</sup>
- Wearables that can monitor disease state
  - Blood sugar and diabetes monitoring connected to the cloud - Glooko
  - Parkinson's disease monitoring<sup>2</sup>







1 15 healthcare gamification startups to watch

2 Home monitoring of patients with Parkinson's disease via wearable technology and a web-based application

## **Desktop diagnostics**

- Using standard computers to detect early Alzheimer's up to three years before official diagnosis<sup>1</sup>
- Theranos at every pharmacy and doctor's office giving immediate results
  - Gives more areas access to diagnostics
  - Increases chances treatment can begin immediately





# **Drug/Drug interactions**

- Use anonymized data or personal data shared with a patient's permission<sup>1</sup>
  - Find drugs that should not be mixed
  - One examples: SSRI antidepressants and blood pressure medications
- Use a patient's records to automatically aler providers and druggists



## **Determining facility specialization**

- One example: For some infant cardiac surgeries, if a hospital does a low volume of surgeries, they may have higher mortality rate
- An unanswered question: should patients know the relative success rates of different facilities?
  - If the difference isn't statistically meaningful, how can you let patients know that two facilities are likely the same?



#### **Targeted outreach to save lives**

- Reach out to at-risk populations (as determined from medical records)
- Diabetes, substance abuse, obesity, and other conditions could be helped by early medical intervention driven by analytics<sup>1</sup>
- Treating diabetes saves lives and thousands of dollars in complications per patient per year<sup>2</sup>



2 The economic costs of undiagnosed diabetes

Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes

<sup>1</sup> OPT Playbook Diabetes

## Genetic testing for public health


- Look for pre-dispositions in genetic tests and help patients assess their own risks<sup>1</sup>
- Norway has a great chance to find genes most affecting a majority of its population through widespread, voluntary, genetic testing and intelligent and secure data analysis





# Why stop at genes? Measure RNA, proteins, and metabolites

- Michael Snyder at Stanford found his Type II diabetes<sup>1</sup>
- Predicting the effectiveness of the antidepressant Sertraline from metabolome information<sup>2</sup>



1 Making it personal geneticist michael snyder puts a face to personalized medicine

2 Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept

#### Let's enable the future

- Assure we keep secure information sharing and technology modernization in mind as we plan computing system upgrades
- Keep an eye on advanced genetic, metabolic, and desktop testing
- Look to enable wearables to improve patient access to care